Lipella Pharmaceuticals Inc. (LIPO)

0.00 +0.00% (+0.00)

Over 1Y: -99.9%

2026-08-27
0.2 0.4 0.6
Aug Oct Dec Feb Apr Jun Aug

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q1 '22 — Revenue: 33.1K Q1 '22 — Operating Cash Flow: -699.4K Q1 '22 — Net Income: -738K Q2 '22 — Revenue: 0 Q2 '22 — Operating Cash Flow: -580K Q2 '22 — Net Income: -782K Q3 '22 — Revenue: 0 Q3 '22 — Operating Cash Flow: -320.2K Q3 '22 — Net Income: -713.8K Q4 '22 — Revenue: 151K Q4 '22 — Operating Cash Flow: -231.6K Q4 '22 — Net Income: -363.9K Q1 '23 — Revenue: 118K Q1 '23 — Operating Cash Flow: -1.1M Q1 '23 — Net Income: -1.1M Q2 '23 — Revenue: 106.7K Q2 '23 — Operating Cash Flow: -655.1K Q2 '23 — Net Income: -1.5M Q3 '23 — Revenue: 104.1K Q3 '23 — Operating Cash Flow: -689.4K Q3 '23 — Net Income: -1.3M Q4 '23 — Revenue: 120.8K Q4 '23 — Operating Cash Flow: -727.7K Q4 '23 — Free Cash Flow: -727.7K Q4 '23 — Net Income: -688.9K Q1 '24 — Revenue: 145.9K Q1 '24 — Operating Cash Flow: -1.4M Q1 '24 — Net Income: -1.2M Q2 '24 — Revenue: 136.4K Q2 '24 — Operating Cash Flow: -918.8K Q2 '24 — Net Income: -938.1K Q3 '24 — Revenue: 80.4K Q3 '24 — Operating Cash Flow: -653.1K Q3 '24 — Net Income: -1.4M Q4 '24 — Revenue: 173.7K Q4 '24 — Operating Cash Flow: -990.4K Q4 '24 — Net Income: -1.4M Q1 '25 — Revenue: 129.4K Q1 '25 — Operating Cash Flow: -1.4M Q1 '25 — Net Income: -1.3M Q2 '25 — Revenue: 86.7K Q2 '25 — Operating Cash Flow: -1.4M Q2 '25 — Net Income: -1.3M Q3 '25 — Revenue: 0 Q3 '25 — Operating Cash Flow: -926.1K Q3 '25 — Net Income: -1.3M -1.4M -1.1M -700K -350K 0 350K
Q1 '22 Q3 '22 Q1 '23 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2025-09-30, reported in USD. The newest fact in the filings is dated 2025-09-30, 334 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

3.0
OE margin -1225.2%
Oper. margin -1387.9%
Accruals -23.6%
EBITDA margin -1387.2%
FCF margin -1225.2%
OCF margin -1225.2%
Profit margin -1367.4%
ROA -226.8%
ROCE -316.9%
ROE -358.3%
Capex / sales —
Gross margin —
OCF / EBIT —
ROIC —

4 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.0
RPO / sales —
RPO growth —
Segment HHI —

2 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

6.5
ND/EBITDA —
Interest cover -480.3×
Debt / Eq 0.0×
Debt payback 0.0 yr
Quick ratio 3.2×
Cash runway 0.45 yr
F-score 2.6 pts
Cash / Debt —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

1.0
Sales/sh Y/Y -42.3%
Sales Q/Q -100.0%
Shares change +39.6%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Sales CAGR 4Y —

3 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.